These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 34088832

  • 21. PLX3397, a CSF1 receptor inhibitor, limits allotransplantation-induced vascular remodelling.
    Almonte VM, Uriyanghai U, Egaña-Gorroño L, Parikh D, Oliveira-Paula GH, Zhang J, Jayakumar S, Riascos-Bernal DF, Sibinga NES.
    Cardiovasc Res; 2022 Sep 20; 118(12):2718-2731. PubMed ID: 34478521
    [Abstract] [Full Text] [Related]

  • 22. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
    Lu CS, Shiau AL, Su BH, Hsu TS, Wang CT, Su YC, Tsai MS, Feng YH, Tseng YL, Yen YT, Wu CL, Shieh GS.
    J Hematol Oncol; 2020 Jun 01; 13(1):62. PubMed ID: 32487125
    [Abstract] [Full Text] [Related]

  • 23. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M.
    Neuro Oncol; 2016 Apr 01; 18(4):557-64. PubMed ID: 26449250
    [Abstract] [Full Text] [Related]

  • 24. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG, Gronchi A, Stacchiotti S.
    Expert Rev Clin Pharmacol; 2020 Jun 01; 13(6):571-576. PubMed ID: 32478598
    [Abstract] [Full Text] [Related]

  • 25. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E, Longhi A, Donati DM, Staals EL.
    Expert Rev Anticancer Ther; 2020 Jun 01; 20(6):441-445. PubMed ID: 32297819
    [Abstract] [Full Text] [Related]

  • 26. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
    Wen J, Wang S, Guo R, Liu D.
    Eur J Med Chem; 2023 Jan 05; 245(Pt 1):114884. PubMed ID: 36335744
    [Abstract] [Full Text] [Related]

  • 27. CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model.
    Tan IL, Arifa RDN, Rallapalli H, Kana V, Lao Z, Sanghrajka RM, Sumru Bayin N, Tanne A, Wojcinski A, Korshunov A, Bhardwaj N, Merad M, Turnbull DH, Lafaille JJ, Joyner AL.
    Oncogene; 2021 Jan 05; 40(2):396-407. PubMed ID: 33159168
    [Abstract] [Full Text] [Related]

  • 28. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
    Fang Y, He Y, Wu C, Zhang M, Gu Z, Zhang J, Liu E, Xu Q, Asrorov AM, Huang Y.
    Theranostics; 2021 Jan 05; 11(14):6860-6872. PubMed ID: 34093858
    [Abstract] [Full Text] [Related]

  • 29. Analysis of the effects of M2 macrophage-derived PDE4C on the prognosis, metastasis and immunotherapy benefit of osteosarcoma.
    Pan F, Pan R, Hu R, Zhang H, Lei S, Zhang L, Zhou C, Zeng Z, Tian X, Xie Q.
    J Cell Mol Med; 2024 May 05; 28(10):e18395. PubMed ID: 38774995
    [Abstract] [Full Text] [Related]

  • 30. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.
    Cancer Discov; 2011 Jun 05; 1(1):54-67. PubMed ID: 22039576
    [Abstract] [Full Text] [Related]

  • 31. Identification and Functional Analysis of EPOR+ Tumor-Associated Macrophages in Human Osteosarcoma Lung Metastasis.
    Li Y, Li M, Wei R, Wu J.
    J Immunol Res; 2020 Jun 05; 2020():9374240. PubMed ID: 32908942
    [Abstract] [Full Text] [Related]

  • 32. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
    Lv Q, Zhang Y, Gao W, Wang J, Hu Y, Yang H, Xie Y, Lv Y, Zhang H, Wu D, Hu L, Wang J.
    Pharmacol Res; 2024 Apr 05; 202():107126. PubMed ID: 38432446
    [Abstract] [Full Text] [Related]

  • 33. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG.
    Cancer Immunol Res; 2017 Jul 05; 5(7):535-546. PubMed ID: 28536100
    [Abstract] [Full Text] [Related]

  • 34. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
    Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.
    N Engl J Med; 2015 Jul 30; 373(5):428-37. PubMed ID: 26222558
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
    Awasthi BP, Guragain D, Chaudhary P, Jee JG, Kim JA, Jeong BS.
    Chem Biol Interact; 2023 Jan 05; 369():110255. PubMed ID: 36368339
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.